 Calithera Biosciences Inc NASDAQ: CALA shared interim safety and efficacy results from a Phase 1b trial evaluating CB-280, the companys investigational arginase inhibitor, in adults with cystic fibrosis CF. The data were shared at the North American Cystic Fibrosis Foundation Conference NACFC. 